206,164 Shares in Zoetis Inc. (NYSE:ZTS) Acquired by Aware Super Pty Ltd as trustee of Aware Super

Aware Super Pty Ltd as trustee of Aware Super bought a new stake in Zoetis Inc. (NYSE:ZTS) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 206,164 shares of the company’s stock, valued at approximately $33,590,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Howard Capital Management Group LLC boosted its position in Zoetis by 0.8% during the 3rd quarter. Howard Capital Management Group LLC now owns 104,866 shares of the company’s stock worth $20,489,000 after buying an additional 883 shares during the period. Principal Financial Group Inc. lifted its holdings in shares of Zoetis by 17.3% during the third quarter. Principal Financial Group Inc. now owns 2,377,403 shares of the company’s stock worth $464,497,000 after purchasing an additional 351,372 shares during the period. Diamant Asset Management Inc. grew its stake in shares of Zoetis by 2.4% in the third quarter. Diamant Asset Management Inc. now owns 4,465 shares of the company’s stock worth $872,000 after purchasing an additional 105 shares during the last quarter. World Investment Advisors LLC increased its holdings in Zoetis by 29.1% in the third quarter. World Investment Advisors LLC now owns 34,236 shares of the company’s stock valued at $6,689,000 after purchasing an additional 7,709 shares during the period. Finally, Wilmington Savings Fund Society FSB raised its position in Zoetis by 801.0% during the 3rd quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company’s stock worth $3,635,000 after purchasing an additional 16,541 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Activity at Zoetis

In other Zoetis news, Director Willie M. Reed sold 1,210 shares of the stock in a transaction dated Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares in the company, valued at approximately $2,757,196.26. This represents a 1.98 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. StockNews.com upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Morgan Stanley decreased their price objective on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a research report on Friday, February 14th. Barclays boosted their target price on shares of Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Finally, Piper Sandler lifted their price objective on Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Performance

Shares of ZTS stock opened at $149.40 on Monday. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The firm has a market capitalization of $66.66 billion, a PE ratio of 27.31, a price-to-earnings-growth ratio of 2.78 and a beta of 0.92. The firm has a fifty day simple moving average of $162.51 and a two-hundred day simple moving average of $171.22. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09.

Zoetis (NYSE:ZTS) last posted its earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 26.86% and a return on equity of 53.82%. Analysts forecast that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Investors of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Monday, April 21st. This represents a $2.00 annualized dividend and a yield of 1.34%. Zoetis’s dividend payout ratio (DPR) is currently 36.56%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.